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ABSTRACT 
Background: Screening using fecal occult blood testing (FOBt) reduces colorectal cancer (CRC) 
mortality, but the test has low sensitivity. A 'missed' cancer may cause psychological harms in the 
screened population that partially counteract the benefits of early detection.  
Methods: 311 people diagnosed with CRC: i) after a negative FOBt result (interval cancer), ii) a 
positive result (screen-detected cancer), or iii) in regions where screening was not offered, completed 
questions on quality of life (FACT-C), depression (CES-D),  perceived diagnostic delay, and trust in 
the results of FOBt screening. 15 withheld consent to data matching with medical records, leaving a 
sample size of 296. 
Results: Controlling for demographic and clinical variables, patients with an interval cancer reported 
poorer quality of life (difference in means = 6.16, p = 0.03) and more diagnostic delay (OR: 0.37, p = 
0.02) than patients with screen-detected disease, with no differences in depression. No differences 
were observed between the interval cancer group and the group not offered screening on these 
measures. Patients with an interval cancer reported the lowest levels of trust in FOB testing.  
Conclusions: An interval cancer has adverse effects on trust in FOBt but does not result in worse 
psychological outcomes compared with people diagnosed in areas with no screening programme. 
People with an interval cancer report poorer quality of life than people with screen-detected disease. 
Impact: Improvements in test sensitivity could improve quality of life among people who complete 
an FOB test over and above any benefits already conferred by earlier detection. 
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INTRODUCTION 
Colorectal cancer (CRC) is currently the fourth leading cause of cancer death worldwide (1), but  
mortality rates are declining in developed countries, and approximately half of this reduction has 
been attributed to the introduction of screening (2).  Screening for CRC using fecal occult blood 
testing (FOBt) has been shown to reduce mortality by 16% among people invited to participate, and 
by 25% among those who complete at least one FOB test (3). Screening programmes using FOBt are 
offered in a number of countries (4), and this means that increasing numbers of people will have their 
CRC diagnosed following participation in screening. In order for screening to do ‘more good than 
harm’, adverse effects, including effects on psychological outcomes, need to be kept to a minimum.  
 
To date, research into the psychological impact of CRC screening has been broadly reassuring. No 
evidence of sustained anxiety has been found in people who receive a false positive FOBt result (5). 
Research on people who received a positive result at screening, (combining false positive and true 
positive results, and comparing them to people who had a negative result), has also reported no long 
term effects on anxiety or worry about cancer (6), and no clinically significant effects on screen-
specific anxiety, or quality of life, has been observed among people getting a positive result in fecal 
immunological testing (7). Similarly, research into the detection of pre-cancerous lesions 
(adenomatous polyps) has found little evidence of any impact on worry about cancer, or general 
anxiety (8), and patients diagnosed with colorectal at flexible sigmoidoscopy screening reported 
relief that an earlier diagnosis had prevented a worse outcome than might have occurred in the 
absence of screening. (9)  However, the psychological impact of false negative screening results, 
where the screening result is normal (negative) but the person is later found to have cancer, could 
potentially have a more severe psychological effect, especially if the patient fears that their cancer 
was “missed” at an earlier, more treatable, stage. Systematic reviews show that little research has 
examined the impact of false negative results in cancer screening (10). 
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 An interval CRC is defined as a "colorectal cancer diagnosed after a screening or surveillance exam 
in which no cancer is detected, and before the date of the next recommended exam" (11).  In the 
FOBt pilots that were run in the UK before the introduction of national screening programmes, 
interval cancer rates were between 30 and 50% (12, 13)  While some interval cancers will be 
tumours that developed since the screening test, the majority will have been missed by the test.  False 
negatives are an inevitable part of screening, because most screening tests are less than 100% 
sensitive (14) but there is evidence people incorrectly assume that sensitivity levels are near-perfect 
(15), and attribute screening “failures” either to individual health professionals or laboratories (16).  
In addition, a large proportion of screening participants are unaware they may have a CRC despite a 
negative FOBt result (17). Anger and mistrust in the medical profession have been reported as 
common responses to medical errors in primary care (18), and in the field of antenatal screening, a 
false negative result has been associated with poorer acceptance of a child with Downs’ Syndrome 
than if screening was declined (19).  These findings suggest that if people believe there has been a 
medical “error” or delay in diagnosing their cancer, their adjustment may be compromised as a 
result. The aims of the present study were to test the hypotheses that patients with an interval CRC 
would have poorer quality of life, higher depression, greater perceived diagnostic delay, and lower 
trust in the results of FOBt screening, than either people with screen-detected CRC, or people 
diagnosed with CRC in areas of the country where screening was not offered. 
 
Ethical approval and patient consent 
Ethical approval was obtained from Riverside Research Ethics Committee (reference number: 
09/H0706/41). Additional approval for identifying potential participants via database linkage was 
granted by the NHS National Services Scotland Privacy Advisory Committee, and the NHS National 
Services Scotland Community Health Index Advisory Group. Patient consent was implied by the 
completion and return of the questionnaire. 
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MATERIALS AND METHODS 
This was a cross-sectional study, comparing three groups of patients diagnosed with CRC. The first 
two groups were participants in the Scottish Demonstration Pilot of FOBt Screening for Colorectal 
Cancer, which ran between 2000-2007, and were either diagnosed with CRC after a negative test 
result (the interval cancer group) or after a positive test result (the screen-detected group). The third 
group was diagnosed with CRC during the same period, but had not been invited for screening 
because they lived outside the area covered by the pilot programme. A questionnaire assessing 
psychological outcomes was mailed to General Practices to send on to the identified patients in June 
2012, with a reminder survey sent on to non-responders in September 2012. 
 
Our sample size was calculated to detect a medium effect size (d = 0.5) with alpha = 0.05 and power 
= 0.95 between three groups (20).  The effect size of 0.5 is considered the minimal important 
difference in quality of life measures (21), defined as the smallest difference that patients view as 
important (beneficial or harmful), and would result in a doctor considering a change in the patient’s 
management (22). The number of responses required was 249. Based on previous mailed surveys 
with cancer patients (23) we anticipated a response rate of 60%; hence a minimum of 415 
participants needed to be invited to reach this number. Study attrition due to patients not meeting 
inclusion criteria, or general practitioners (GPs) not wishing to take part in the research, was 
unknown, but was estimated at 35% (20% for patient exclusion (24) and 15% for GP non-
participation), leaving a total sample size of 639 as the initial target. 
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Participants and recruitment 
Potential participants were identified by linking the Scottish Cancer Registry and Scottish Colorectal 
Cancer Screening Pilot databases by their Community Health Index (CHI) number. Patients not 
offered screening were resident outside the pilot areas (i.e. not in NHS Fife, NHS Grampian or NHS 
Tayside), and were identified as having a diagnosis of CRC using the Scottish Cancer Registry (ICD 
10 C18-C20). Selection of patients in the group not offered screening was limited to people aged 50 
to 69 at diagnosis, who were diagnosed within the time periods of the three rounds of the Pilot. 
Patients with an interval cancer were identified by matching the individuals invited to participate in 
the Scottish Colorectal Cancer Screening Pilot with the Scottish Cancer Registry, and establishing 
that their cancer had been diagnosed within two years of a negative screening result. Patients with 
screen-detected CRC were identified from the Scottish Colorectal Cancer Screening Pilot database. 
For each group, individuals were randomly selected, stratified by sex, from the relevant database 
pool. The CHI database was used to identify patients and GP details. The CHI is a unique identifier 
for individuals registered at general practices in Scotland, and contains information on date of birth 
and gender.  
 
Practitioner Services Division at NHS National Services Scotland (NSS) co-ordinated patient contact 
via patient GPs. Patients identified as deceased, or as having moved from the area, were excluded. 
Practitioner Services Division were given template letters for GPs and patients; they added GP and 
patient details, and forwarded the letters to the GPs to pass on to eligible patients. This process was 
approved by the Riverside Research Ethics Committee, NHS NSS Privacy Advisory Committee, and 
the NHS NSS Community Health Index Advisory Committee.  GPs were asked to confirm the 
diagnosis of CRC, and exclude patients who were deceased or terminally ill, unable to speak or read 
English, or lacked the capacity to take some or all decisions for themselves because of mental 
disorder or inability to communicate. 
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Measures 
The primary outcome was quality of life specific to CRC which was measured using the FACT-C 
(25); participants were asked to indicate how they had been feeling during the past 7 days. Secondary 
outcomes were depression, perceived delay, and trust in FOBt.  Depression was measured with the 
10 item version of the Center for Epidemiological Studies Depression scale (CES-D) (26) asking 
people about their mood over the last three months. Perceived diagnostic delay was assessed with the 
item: “Do you think your cancer could have been diagnosed sooner than it was” with response 
options: “yes”, “no”, and “not sure”.  Trust in the results of FOBt screening was assessed with the 
item: “If you were to have an FOB test, would you trust the results of the test” with response options: 
“not at all”, “somewhat”, “moderately”, and “very much” (from (27) with the addition of the 
response option “moderately”).  
Age, gender, Scottish Index of Multiple Deprivation (SIMD) (28), years since diagnosis (length of 
time between diagnosis and completion of the questionnaire), Dukes’ stage, and treatment received 
(radiotherapy, chemotherapy) were covariates. These were supplied by NHS NSS with patient 
consent. Co-morbidities were self-reported and combined into a single variable “comorbidity” 
(Yes/No).  Ethnicity and employment status were collected in the questionnaire for the purpose of 
describing the sample.  
 
Statistical analysis 
Predictors of quality of life, depression, and trust in the results of FOBt screening were analysed 
using linear regression, with diagnostic group dummy coded, and the interval cancer group entered 
as the reference category.  Predictors of perceived diagnostic delay were analysed using logistic 
regression with the response options “not sure” and “no” combined. Regression analyses were 
repeated controlling for age, gender, deprivation, time since diagnosis, receipt of radiotherapy or 
chemotherapy, and presence of comorbidities; Dukes’ stage at diagnosis was not included, because it 
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correlated highly with having chemotherapy, and had higher rates of missing data than the 
chemotherapy variable. The same pattern of results was observed if Dukes’ stage was entered into 
the analysis instead of receipt of chemotherapy. All statistical analyses were two-side and performed 
using SPSS version 20.  
 
Response rate 
GPs were sent the research invitation letters for 675 patients, of whom 142 were not contacted 
because the GP indicated that the patient met one or more of the exclusion criteria (n=70), or the GP 
did not wish to participate in the research (n=72); leaving 533 patients who were (apparently) mailed 
a questionnaire. Patients were invited to return the questionnaire blank if they did not wish to 
participate, but unless the questionnaire was returned, there was no way of confirming that it had 
definitely been forwarded to the patient. Assuming that all non-returned questionnaires had been 
mailed out, the questionnaire response rate was 58.3% (N=311), of whom 15 withheld consent for 
data-matching to NSS.  This left 296 as the principal sample for analysis; a response rate of 55.5%.  
There were 91 in the group not offered screening, 106 in the screen-detected group, and 99 in the 
interval cancer group.  
 
Scores on the FACT-C and CES-D were only computed if patients had answered at least 50% of the 
items (or 50% of the items of subscales in the case of the FACT-C), otherwise they were recorded as 
missing. Missing data were 5% or higher for Dukes’ stage, receipt of radiotherapy, and the FACT-C, 
but less than 5%  for all the other variables (see Tables 1 and 2). The proportion of missing data on 
the FACT-C was unrelated to group status. Linear and logistic regressions were run both with 
complete cases, and with data imputed for missing values, using multiple imputation (29). 
 
  
Psychological impact of interval cancers 
 
10 
 
RESULTS 
Background variables 
Descriptive and clinical characteristics of the whole sample, and the three groups separately, are 
shown in Tables 1 and 2.  The average age was 69 years, ranging from 56 to 81; consistent with the 
age of invitation to the Scottish Colorectal Cancer Screening Pilot (50-69) and time since diagnosis. 
Time since diagnosis ranged from 3.5 to 12 years.  The sample was less deprived than the general 
population of Scotland, with more than 20% in each of the higher quintiles.  The current sample 
reported similar quality of life scores to those reported in other studies of people with CRC (25, 30).   
 
Controlling for age, gender, deprivation, time since diagnosis, treatment (chemotherapy or 
radiotherapy), and comorbidities, patients with an interval cancer reported poorer quality of life and 
were more likely to perceive a delay in their diagnosis than patients with screen–detected disease, 
although there were no differences in depression between the two groups (see Table 3).  However 
patients with an interval cancer did not differ on quality of life, depression, or perceptions of 
diagnostic delay, compared with patients who had not been offered screening. Patients with an 
interval cancer reported lower trust in the results of FOB testing than patients in areas where 
screening was not offered and patients with screen-detected disease (see Table 3). Group differences 
in quality of life, depression, perceived diagnostic delay, and trust in the results of FOB testing, 
remained the same when analyses were re-run using multiple imputation for missing data.  
 
DISCUSSION 
Patients who had an interval CRC showed no evidence of worse quality of life, depression, or 
perceived delay in having their cancer diagnosed, than patients who had not been invited for 
screening, but they did have worse quality of life and higher perceived delay, than patients who 
received a screen-detected diagnosis. These results are reassuring in terms of concern about 
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additional psychological harms associated with an interval cancer.  The most plausible interpretation 
of the pattern of differences between the three groups is that a screen-detected CRC diagnosis has a 
longer-term protective effect on quality of life, even after controlling for many possible confounders.  
This is a positive finding for CRC screening. As might be expected, patients diagnosed with CRC 
after a negative screening result reported lower trust in the results of FOBt screening, and this is 
potentially a cause for concern. Medical mistrust has been associated with reduced willingness to 
undergo cancer screening, particularly among ethnic minority groups and people with lower socio-
economic status (31-33). These studies assessed trust in ‘medical people’ among members of the 
public, the majority of whom would not have had cancer. Mistrust in the results of a specific test 
among people who had an interval cancer may have different effects on behaviour. In the UK at 
least, people with an interval cancer would not be offered another FOB test, but would be put on a 
surveillance schedule involving regular colonoscopies, CT scans and blood tests. However, it is 
possible that mistrust among this patient group could affect screening participation among their 
friends and family. Given the current interval cancer rate associated with FOBt screening, it could be 
argued that the levels of trust in FOBt screening among people with an interval cancer are more 
realistic than those among people with screen-detected disease. Either way, efforts should be focused 
on improving the public’s understanding of the limitations of screening tests.   
 
This is the first study to examine the psychological consequences of having an interval cancer, and 
benefits from validated measures of quality of life and depression, and data derived from NHS 
records on demographic and clinical characteristics except for comorbidities. Although there was 
more than 5% missing data, which raises concern about bias, rates of missing data were similar 
across groups, and the results remained the same when data were imputed for missing values. 
Although quality of life, depression and trust in FOB tests were assessed at the time of the survey, 
perceived diagnostic delay was assessed retrospectively and may have reduced over time. 
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The sample was less deprived than the general population of Scotland; but uptake of FOBt screening 
is itself related to (lower) deprivation (34), and hence the sample fits the profile of people who attend 
screening, so it may not limit the generalisability of the results.  Other factors, however, might 
influence generalisability: response rates were below 60% and responders were almost exclusively 
from white ethnic backgrounds, with non-metastatic disease. No data was available on the GP 
practices who took part in the study. This is because of the way the study datasets were linked, with 
GP details being added at the end, and therefore not appearing in the study dataset. There was 
therefore no way of comparing GP responders with non-responders to see whether GP response was 
biased and any implications this might have had for the results of the study.  The context of the study 
was the pilot screening programme run in Scotland, and public expectations about the programme 
may have been lower than in screening programmes that have been running for longer. This means 
that differences between the interval and not-offered-screening groups may be more apparent in the 
future. In addition, there may be cultural differences in expectations about the quality and accuracy 
of screening programmes, and different responses may be observed in other countries and ethnic 
groups. 
 
Having a cancer “missed” at FOBt screening can be attributed to the cancer not bleeding at the time 
of the test, rather than a poor quality test or human error.  This may mean that adverse psychological 
outcomes would be lower than for interval cancers in other screening programmes (e.g.  breast) 
where attributions of blame to other people or the quality of the service could more easily be made. 
Finally, patients were, on average, six to eight years post-diagnosis, and any adverse psychological 
impact of an interval cancer might have attenuated over time, or be absent, as a result of survivor 
bias and the fact that any delay in diagnosis had not proved fatal.  
 
Psychological impact of interval cancers 
 
13 
 
We are not aware of any other studies examining the psychological outcomes associated with an 
interval cancer with which to compare these results.  Two prospective studies on breast cancer 
patients found no differences between women with a screen-detected versus symptomatically-
detected (i.e. non-screened) breast cancer in psychiatric morbidity (35) or affective disorder (36), but 
did not focus on whether the non-screen-detected cases were interval cancers. Psychological effects 
following screening are more likely to be detected using cancer-specific rather than generic measures 
(such as anxiety or depression) (37, 38) so it is an advantage that the present study assessed cancer-
specific measure of quality of life as well as depression.  
 
The reasons for better longer-term quality of life among people with screen-detected CRC are 
unknown, although previous research has indicated that patients diagnosed at screening perceive 
themselves to be “lucky” to have benefited from early detection.  But there may be other 
explanations: screening is more likely to detect cancers in the left side of the colon (39), and future 
research could assess differences in quality of life by tumour location, as well as differences in 
treatment outcomes or patient experiences, that might contribute to superior longer term quality of 
life among people with screen-detected CRC.  More research is needed into public understanding of 
the risks of a false negative result at screening.  This could indicate a need for patient education to 
promote better understanding of the limitations of CRC screening tests, and ensure that patients 
receiving a negative result do not experience false reassurance or ignore subsequent cancer 
symptoms.  Given the likelihood of interval cancers, it is important to consider how trust in the 
screening programme can be maintained into the future.
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Table 1: Demographic characteristics of patients with different screening histories. Values are 
numbers (percentages) unless stated otherwise 
 Overall 
(N=296) 
Interval 
(n=99)  
 
Screen-
detected 
(n=106) 
Not offered 
screening 
(n=91) 
p value  
Age when completed 
study (years)
a
,
 
mean 
(SD)
 
69.0 (5.8) 68.5 (5.9) 69.8 (5.7) 68.4 (5.7) 0.17 
Men 
a
 146 (49) 44 (44) 56 (53) 46 (51) 0.47 
Scottish Index of 
Multiple Deprivation 
(fifths) 
b
 
    0.29 
1 (most deprived) 22 (8) 9 (9) 7 (7) 6 (7)  
2 50 (17) 14 (15) 17 (16) 19 (21)  
3 71 (24) 21 (22) 28 (26) 22 (24)  
4 79 (27) 35 (36) 24 (23) 20 (22)  
5 (least deprived) 71 (24) 17 (18) 30 (28) 24 (26)  
Employment status 
b
     0.25 
Working (full-
time, part-time, 
self-employed) 
54 (18) 25 (26) 16 (15) 13 (14)  
Retired 220 (75) 66 (67) 82 (78) 72 (80)  
Other (home 
maker, students, 
unemployed, too ill 
to work/ disabled) 
19 (7) 7 (7) 7 (7) 5 (6)  
Ethnic group 
b
     - 
White  291 (99) 98 (99) 103 (98) 90 (100)  
Non-white 3 (1) 1 (1) 2 (2) 0 (0)  
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a
= no missing data; 
b
= missing data <5%; Where there are missing data, percent is valid percent.   
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Table 2: Clinical characteristics of people with different screening histories. Values are numbers 
(percentages) unless stated otherwise 
 Overall Interval Screen-
detected 
Not offered 
screening 
p value * 
Time since diagnosis 
(years),
a 
mean (SD)  
7.7 (2.2) 6.6 (2.2) 
de 
8.6 (1.8) 
f 
7.7 (1.9) <0.001 
Dukes’ stage c     0.04  
A 68 (26) 21 (23) 
d
 32 (35) 
f 
15 (18)  
B 104 (40) 37 (41) 33 (37) 34 (42)  
C 84 (32) 31 (34) 24 (27) 29 (36)  
D 6 (2) 2 (2) 1 (1) 3 (4)  
Surgery 
b
     - 
Yes 286 (98) 95 (99) 100 (94) 91 (100)  
No 7 (2) 1 (1) 6 (6) 0 (0)  
Radiotherapy 
c
     .22 
Yes 37 (14) 16 (18) 
(e) 
13 (13) 8 (9)  
No 238 (86) 71 (82) 89 (87) 78 (91)   
Chemotherapy 
b
     .08 
Yes 119 (42) 43 (47) 
d
 34 (33) 
(f)
 42 (47)  
No 163 (58) 48 (53) 68 (67)  47 (53)  
Comorbidities 
a
     .20 
Yes 208 (70) 69 (70) 
(e) 
69 (65) 70 (77)  
No 88 (30) 30 (30) 35 (37) 21 (23)  
 
a
= no missing data; 
b
= missing data <5%; 
c
= missing data >5%. Where there are missing data, percent is valid 
percent.   
d 
 Significant difference between Interval cancer and Screen-detected cancer groups (d) approaches significance 
e
 Significant difference between Interval and Non-screened cancer groups (e) approaches significance 
f
 Significant difference between Screen-detected and Non-screened cancer groups (f) approaches significance
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Table 3: Quality of life specific to colorectal cancer, depression, perceived diagnostic delay, and trust in the results of any future FOB testing 
among patients with different screening histories. Figures are means (figures for delay are frequencies and odds ratios). 
 
  Comparison with screen-detected Comparison with not offered screening 
Variables Interval 
cancer  
Screen-
detected 
Unadjusted 
difference 
(95% CIs) 
p value Adjusted 
difference
d
 
(95% CIs)  
p value Not offered 
screening 
Difference 
(95% CIs) 
p 
value 
Adjusted 
difference
d
 
(95% CIs) 
p 
value 
Quality of life  
(FACT-C) 
c
 
(0-136) 
108.26 
(18.37) 
(n=90) 
116.57 
(13.63) 
(n=94) 
8.31 
(3.43 to 
13.20) 
<0.001 6.16  
(0.65 to 
11.66) 
0.03 110.67 
(18.53) 
(n=82) 
2.41 
(-2.65 to 7.47) 
0.35 1.70 
(-3.67 to 7.07) 
0.54 
Depression 
b
 
(0-30) 
5.23 
(4.54) 
(n=98) 
3.97 
(4.14) 
(n=105) 
-1.26 
(-0.03 to -
2.49) 
0.05 -0.68  
(-2.05 to 
0.69) 
0.33 5.36 (4.72) 
(n=87) 
0.14  
(-1.15 to 1.42) 
0.838 0.39  
(-0.97 to 0.74) 
0.58 
Perceived 
diagnostic 
delay  
(n and (%) yes 
vs no or not 
sure) 
b
 
30 (31) 15 (14) OR: 0.37 
(0.19 to 
0.75) 
0.01 OR: 0.37 
(0.17 to 
0.83) 
0.02 34 (37) OR: 1.33 (0.73 
to 2.44) 
0.353 OR: 1.21 (0.61 
to 2.41) 
0.58 
Trust in the 
results if were 
to have an 
FOB test 
(1-4)
 b
 
2.74 
(1.06) 
(n=99) 
3.84 
(0.46) 
(n=105) 
1.10 
(0.90 to 
1.31) 
<0.001 1.11  
(0.87 to 
1.35) 
<0.001 3.60 (0.56) 
(n=89) 
0.86 
(0.65 to 1.07) 
<0.001 0.86  
(0.63 to 1.09) 
<0.001 
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a
= no missing data; 
b
= missing data <5%; 
c
= missing data >5%.
  
d
 adjusted for age, gender, deprivation, time since diagnosis, receipt of radiotherapy or chemotherapy, and presence of comorbidities. 
 
 
